Tuesday, February 17, 2026
ADVT 
International

Protest against Waqf Act will continue, says Congress MLA Arif Masood

Darpan News Desk IANS, 10 Apr, 2025 12:25 PM
  • Protest against Waqf Act will continue, says Congress MLA Arif Masood

Bhopal, April 10 (IANS) Congress MLA Arif Masood, who organised a protest against the Waqf (Amendment) Act in Bhopal on Thursday, reiterated that the Muslim community will never accept this newly enacted law and the protests against it will continue.

Addressing a large gathering of the people from the Muslim community, Masood, who is MLA from Bhopal Madhya assembly seat, said, “All India Muslim Personal Law Board (AIMPLB) has always opposed the Waqf Act and will continue to oppose at each level.”

He further alleged that this law was brought not to protect Waqf, reiterating that the BJP-led government has imposed the Waqf (Amendment) Act forcefully on the Muslim community.

“Protest against this law will continue until the Centre withdraws it,” he claimed.

Notably, after the Waqf (Ammendment) Bill-2025 was passed in both the Houses of the Parliament, President Draupadi Murmu on April 5 gave her assent to it, becoming an Act, which came into effect from April 8.

Over 10 petitions, including those by politicians and the All India Muslim Personal Law Board (AIMPLB) and Jamiat Ulama-i-Hind, were filed in the Supreme Court (SC) to challenge the validity of the new law.

The petitioners have submitted that the provisions of the law discriminated against Muslims by imposing restrictions which were not part of the governance of other religious endowments.

The SC bench headed by Chief Justice of India (CJI) Sanjiv Khanna is scheduled to hear the matter on April 16.

The Centre has already filed a caveat in the apex court to ensure no order is passed without hearing it first.

Responding to Aarif Masood’s statement, BJP MLA and Minister, Wiswas Sarang, said that the large Muslim population has welcomed the Waqf Act.

He said only some Muslim leaders, who have illegally encroached Waqf properties, are opposing it for their personal gain.

MORE International ARTICLES

Extra safety scrutiny planned as virus vaccine worries grow

Extra safety scrutiny planned as virus vaccine worries grow
The poll from The Associated Press-NORC Center for Public Affairs Research found only 46% of Americans want a COVID-19 vaccine and another 29% are unsure.

Extra safety scrutiny planned as virus vaccine worries grow

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout
The COLA affects the personal finances of about 1 in 5 Americans, including Social Security recipients, disabled veterans and federal retirees, some 70 million people in all.

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout

AP-NORC poll: New angst for caregivers in time of COVID-19

AP-NORC poll: New angst for caregivers in time of COVID-19
The Associated Press-NORC Center for Public Affairs Research poll finds that 17% of Americans say they are providing ongoing caregiving, part of an informal volunteer corps.

AP-NORC poll: New angst for caregivers in time of COVID-19

Am I immune to the coronavirus if I’ve already had it?

Am I immune to the coronavirus if I’ve already had it?
Reinfection so far has been rare. The best known example: Researchers in Hong Kong said a man had mild COVID-19 and then months later was infected again but showed no symptoms.

Am I immune to the coronavirus if I’ve already had it?

Antibody drugs are no cure but seem promising for COVID-19

Antibody drugs are no cure but seem promising for COVID-19
Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines mimic an infection to spur antibody production.

Antibody drugs are no cure but seem promising for COVID-19

Lilly seeks emergency use of its antibody drug for COVID-19

Lilly seeks emergency use of its antibody drug for COVID-19
Eli Lilly and Company announced the partial results Wednesday in a news release; they have not yet been published or reviewed by independent scientists.

Lilly seeks emergency use of its antibody drug for COVID-19